Workup and Management of Unilateral Pulmonary Neuroendocrine Tumors
Surgery is the definitive treatment for localized pulmonary carcinoids, with the goal of complete tumor removal while preserving as much lung tissue as possible—anatomic resection is preferred for atypical carcinoids while lung-sparing approaches may suffice for typical carcinoids. 1, 2
Initial Diagnostic Workup
Imaging Protocol
- CT chest with contrast is the diagnostic gold standard—use standard lung CT acquisition with 20-second delay post-contrast for optimal mediastinal enhancement 1, 2
- Multiphasic CT abdomen or MRI abdomen to evaluate for metastatic disease, particularly liver metastases 1, 2
- SSTR-PET imaging (Ga-68 DOTATATE) should replace Octreoscan—visualizes ~80% of primary tumors and is most sensitive for metastatic disease 1, 2
Tissue Diagnosis Strategy
The biopsy approach depends on tumor location 1:
- Central tumors: Bronchoscopic biopsy
- Peripheral tumors: Transthoracic biopsy
- Suspected mediastinal nodes: EBUS-guided biopsy in selected cases
- Metastatic disease: Biopsy most accessible site
Critical caveat: Prefer endobronchial biopsy or surgical resection over cytology alone—cytology may not reliably differentiate typical from atypical carcinoid 1. Pathology must evaluate mitotic index (mitoses per 2 mm²) and necrosis to distinguish TC from AC.
Biochemical Assessment
Limit baseline testing to 2:
- Renal function, calcium, glucose
- Plasma chromogranin A (though sensitivity is only 62% with poor predictive value in lung NETs) 1
- 24-hour urine 5-HIAA only if carcinoid syndrome suspected (rare—occurs in 2-5% of cases, usually with liver metastases) 1, 2
- ACTH and cortisol studies if Cushing syndrome suspected (1-6% of cases; up to 40% of ectopic Cushing's are from pulmonary carcinoids) 2
MEN1 Screening
Screen for MEN1 if suggestive family history or clinical features present 2:
- Ionized serum calcium
- Intact parathyroid hormone
- Prolactin
- Consider MEN1 gene mutational analysis if indicated
Surgical Management
Complete surgical resection is the most significant prognostic factor for localized carcinoids 2, 3.
Extent of Resection
- Typical carcinoids: Non-anatomical lung resection (wedge) may be sufficient for small lesions, though segmentectomy provides oncologic resection with parenchymal preservation 2, 4, 3
- Atypical carcinoids: Anatomic lung resection (lobectomy or segmentectomy) should be preferred due to higher recurrence rates 2, 3
- Radical mediastinal lymph node dissection should be performed for both TC and AC 3
Important nuance: N2 staging does not represent an absolute contraindication for surgery given the indolent course in many patients 2. In atypical carcinoids, 66% of patients with metastasis or local recurrence had lymph node involvement, and nodal invasion significantly influences prognosis 2.
Metastatic Disease
- Resection of metastases should be considered whenever possible with curative intent 2
- Surgical metastasectomy is reasonable for resectable metastatic disease 3
Medical Management for Advanced/Unresectable Disease
First-Line Systemic Therapy
Somatostatin analogs (SSAs) are first-line treatment for both carcinoid syndrome control and antiproliferative effect in unresectable disease 2:
- Octreotide LAR or lanreotide are reasonable options
- Particularly effective for low-grade TC and AC
Additional Systemic Options
- Everolimus: Approved for use in pulmonary carcinoids with targeted therapy benefit 5
- Peptide receptor radionuclide therapy (PRRT): Consider for metastatic disease—has shown increased survival and symptom reduction 2, 5
- Locoregional therapies: Should be considered for metastatic disease 2
Chemotherapy
Reserved for progressive disease 2:
- Etoposide and platinum combination most commonly used
- Temozolomide has shown most clinical benefit among cytotoxic regimens
- Overall, cytotoxic regimens demonstrate limited effects
Follow-Up Considerations
These are complex tumors requiring multidisciplinary tumor board discussion and long-term follow-up 2. The multidisciplinary team should include surgeons, medical and radiation oncologists, pulmonologists, and pathologists with specific NET expertise 1, 6.
Common Pitfalls to Avoid
- Don't rely on Ki-67 alone to differentiate TC from AC—it's validated for separating high-grade tumors (SCLC, LCNEC) from carcinoids but not for TC vs AC distinction 1
- Don't skip functional imaging if mass is suggestive of NET but not amenable to biopsy—proceed to SSTR-PET or FDG-PET 1
- Don't assume asymptomatic means benign—over 40% are detected incidentally, and atypical carcinoids have malignant potential requiring systematic follow-up 7, 8